Pixantrone beyond monotherapy: a review

Show full item record



Permalink

http://hdl.handle.net/10138/306577

Citation

Barrenetxea Lekue , C , Grasso Cicala , S , Leppä , S , Stauffer Larsen , T , Herráez Rodríguez , S , Alonso Caballero , C , Jørgensen , J M , Toldbod , H , Leal Martínez , I & D’Amore , F 2019 , ' Pixantrone beyond monotherapy: a review ' , Annals of Hematology , vol. 98 , no. 9 , pp. 2025-2033 . https://doi.org/10.1007/s00277-019-03749-0

Title: Pixantrone beyond monotherapy: a review
Author: Barrenetxea Lekue, Cristina; Grasso Cicala, Silvina; Leppä, Sirpa; Stauffer Larsen, Thomas; Herráez Rodríguez, Susana; Alonso Caballero, Clara; Jørgensen, Judit M.; Toldbod, Helle; Leal Martínez, Irene; D’Amore, Francesco
Contributor: University of Helsinki, Department of Oncology
Date: 2019-09
Language: eng
Number of pages: 9
Belongs to series: Annals of Hematology
ISSN: 1432-0584
URI: http://hdl.handle.net/10138/306577
Abstract: Outcomes for patients with non-Hodgkin’s lymphoma (NHL) that proves refractory to treatment remain poor. Treatment of such patients is individualized and can include enrolment in a clinical trial of novel agents or use of one of a wide array of drug regimens. Initial treatment with anthracyclines such as doxorubicin limits options at later stages of treatment because of anthracycline-related cumulative cardiotoxicity. The aza-anthracenedione pixantrone was developed to reduce the likelihood of cardiotoxicity without compromising efficacy and is currently conditionally approved for use as monotherapy in patients with multiply-relapsed or refractory aggressive B cell NHL. The use of pixantrone in combination therapy, often to replace doxorubicin or mitoxantrone, has or is currently being investigated in numerous studies in patients with aggressive or indolent NHL and is the focus of this review. These include the R-CPOP regimen (rituximab, cyclophosphamide, pixantrone, vincristine, prednisone) for aggressive NHL in the first-line setting, including a study in elderly patients with limited cardiac function, and for patients with relapsed NHL with prior anthracycline exposure; the PSHAP regimen (pixantrone, cytarabine, prednisone, cisplatin), also in the latter setting; the PREBen/PEBen regimen (pixantrone, bendamustine and etoposide with or without rituximab) as salvage therapy; and pixantrone in combination with fludarabine, dexamethasone, and rituximab (FPD-R) for relapsed indolent NHL.
Subject: 3121 General medicine, internal medicine and other clinical medicine
Pixantrone
Non-Hodgkin's lymphoma
Antineoplastic efficacy
Cardiotoxicity
CLINICAL-PRACTICE GUIDELINES
NON-HODGKIN-LYMPHOMA
OBINUTUZUMAB GA101
CELL LYMPHOMAS
ADULT PATIENTS
PHASE-I/II
OPEN-LABEL
COMBINATION
DOXORUBICIN
DIAGNOSIS
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
BarrenetxeaLeku ... neBeyondMonotherapyARe.pdf 343.4Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record